Patents by Inventor Matthias Lohmann

Matthias Lohmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 10392366
    Abstract: The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: August 27, 2019
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Christoph Pöverlein, Kurt Ritter, Nis Halland, Matthias Lohmann
  • AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20180237419
    Abstract: The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 23, 2018
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Christoph Poverlein, Kurt Ritter, Nis Halland, Matthias Lohmann
  • Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9908868
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9896434
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Serpins: methods of therapeutic ?-cell regeneration and function
    Patent number: 9763998
    Abstract: Compositions and methods of use are provided for improving ? cell function and promoting pancreatic ? cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: September 19, 2017
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Rohit N. Kulkarni, Abdelfattah El Ouaamari, Daniel Margerie, Matthias Lohmann, Jean Claude Guillemot, Denis Loyaux
  • Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9758520
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170029405
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 2, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022198
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022182
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • SERPINS: METHODS OF THERAPEUTIC BETA-CELL REGENERATION AND FUNCTION
    Publication number: 20160002316
    Abstract: Compositions and methods of use are provided for improving ? cell function and promoting pancreatic ? cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 7, 2016
    Applicants: JOSLIN DIABETES CENTER, SANOFI
    Inventors: Daniel MARGERIE, Matthias LOHMANN, Jean Claude GUILLEMOT, Denis LOYAUX, Rohit KULKARNI, Abdelfattah EL OUAAMARI
  • SERPINS: METHODS OF THERAPEUTIC B-CELL REGENERATION AND FUNCTION
    Publication number: 20150366940
    Abstract: Compositions and methods of use are provided for improving ? cell function and promoting pancreatic ? cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.
    Type: Application
    Filed: February 21, 2014
    Publication date: December 24, 2015
    Inventors: Rohit N. Kulkarni, Abdelfattah El Ouaamari, Daniel Margerie, Matthias Lohmann, Jean Claude Guillemot, Denis Loyaux